Thermo Fisher Scientific (TMO) EBT Margin (2009 - 2026)

Thermo Fisher Scientific has disclosed EBT Margin across 18 years of filings, most recently posting 15.76% for Q1 2026.

• Quarterly EBT Margin rose 13.0% year-over-year to 15.76% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 16.42% (down 5.0% YoY) and the FY2025 annual result came in at 16.4%, down 1.0% from the prior year.
• EBT Margin retreated to 15.76% in Q1 2026, from 17.63% in the prior quarter.
• Over five years, EBT Margin peaked at 21.49% in Q2 2022 and troughed at 12.73% in Q2 2023.
• A 5-year average of 16.18% and a median of 15.98% in 2023 frame the typical range for EBT Margin.
• Annual changes were most pronounced in 2023 — EBT Margin slumped 877 bps — and 2024, when it soared 336 bps.
• Tracing TMO's EBT Margin over 5 years: stood at 15.52% in 2022, then gained by 3 bps to 15.98% in 2023, then climbed by 7 bps to 17.03% in 2024, then advanced by 3 bps to 17.63% in 2025, then dropped by 11 bps to 15.76% in 2026.
• Business Quant data shows TMO's EBT Margin at 15.76% in Q1 2026, 17.63% in Q4 2025, and 16.42% in Q3 2025.